-
Uncategorized3 weeks agoSTAT+: Kennedy names interim surgeon general amid vacancies atop health department
WASHINGTON — Health secretary Robert F. Kennedy Jr. has elevated a senior health official to serve as an interim surgeon general until that position is filled...
-
Uncategorized3 weeks ago
Pazdur declines to announce candidacy for vacated FDA commissioner role
Pazdur declines to announce candidacy for vacated FDA commissioner role
-
Uncategorized3 weeks ago
Fetal gene therapy’s progress calls into question the taboo on embryo editing
BOSTON — Over the past year, I’ve begun hearing rumblings from scientists who secretly think it’s time to stop being stodgy about editing the genes of...
-
Uncategorized3 weeks ago
Moderna’s stock rides hantavirus fears as spotlight returns to infectious disease platform
While the pathogen appears unlikely to trigger a pandemic, analysts see potential for Moderna to build goodwill amid a period of political pressure on vaccine manufacturers.
-
Uncategorized3 weeks ago
GHO Capital, CBC Group plan to merge, forming $21B healthcare investment firm
London-based Global Healthcare Opportunities and Singapore-based CBC Group announced plans to merge, creating what they called the largest healthcare-focused investment manager, with over $21 billion in...
-
Uncategorized3 weeks agoThere’s a leadership vacuum at NIH, too
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. Here in Boston, yesterday was the...
-
Uncategorized3 weeks ago
Beam one-ups Wave as both show promise of editing for AATD
While both Beam Therapeutics and Wave Life Sciences touted notable biomarker benefits for their respective alpha-1 antitrypsin deficiency assets, analysts said that Beam might have the...
-
Uncategorized3 weeks ago
Beam one-ups Wave as both show promise of genetic editing for AATD
While both Beam Therapeutics and Wave Life Sciences touted notable biomarker benefits for their respective alpha-1 antitrypsin deficiency assets, analysts said that Beam might have the...
-
Uncategorized3 weeks ago
AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritis
UCB’s Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie’s Skyrizi in a Phase 3 head-to-head study of psoriatic arthritis.
-
Uncategorized3 weeks agoAfter Rubio’s critique, WHO defends work on Ebola response
World Health Organization officials on Wednesday mounted a defense of their response to the new and worrisome Ebola outbreak centered in the Democratic Republic of the...
Amgen shores up Tavneos’ FDA defense with Duke data analysis
